Hospitals are facing increasingly burdensome policies from commercial insurers, leading to problems with cash flow and patient safety. Hospital executives think federal regulators need to enact stricter policies that require payers to operate on faster timelines, as well as provide more transparency into their reasons for denying claims. The post Payers Are Putting Profit Over…
WebMD Ignite recently introduced Coach, a solution that supports health plans’ care management programs. It includes educational resources for members and reporting on member engagement. The post WebMD Ignite Launches New Solution to Improve Health Plan Care Management Programs appeared first on MedCity News.
Johnson & Johnson stopped short of implementing its proposal to alter the way two drugs are paid for under the 340B drug discount program, but the drugmaker made it clear it still wants changes. In other recent regulatory news, we have drug approvals, clinical holds, and one product withdrawal. The post J&J Backs Down From…
People working the most vital occupations, like farmers and ranchers, call the most remote areas in this country home. Their health shouldn’t suffer due to their choice of employment. The post Rural Healthcare Needs More Than Just Telehealth appeared first on MedCity News.
Recently, the Office of Management and Budget has released new procedures to assess government regulation (Circular A-4) and economic policies (Circular A-94). What is unique about this guidance is that it weights benefits and costs of new regulations and policies based on the income of the individuals impacted. The goal is to help reduce inequality….
The Host Julie Rovner KFF Health News @jrovner Read Julie’s stories. Julie Rovner is chief Washington correspondent and host of KFF Health News’ weekly health policy news podcast, “What the Health?” A noted expert on health policy issues, Julie is the author of the critically praised reference book “Health Care Politics and Policy A to…
Recordati is acquiring Sanofi’s Enjaymo, the only approved drug for the rare blood disorder cold agglutinin disease. Achieving sales milestones could bring the deal’s value to more than $1 billion. The post Sanofi Drug for Rare Blood Disease Is Heading to Recordati for $825M appeared first on MedCity News.
Hospital CEO David Berger, M.D., says tools such as ‘Ask Avo’ could transform how clinicians access evidence at the bedside
EY report shows a $9 increase in benefits from the prior year
Walmart’s Cancer Centers of Excellence program historically focused on some of the most prevalent cancers, such as breast, lung, colon, prostate, pancreatic and blood cancer. Now, employees can access the same benefit for a whole host of other cancers, including bone, pituitary, liver, thyroid, central nervous system and gynecological. The post Walmart Expands Centers of…